AbCellera Doses First Patients in Phase 2 Trial of Menopause Drug Candidate

MT Newswires Live01-12

AbCellera Biologics (ABCL) said Monday the first patients were dosed in the phase 2 portion of its phase 1/2 trial of ABCL635, an experimental antibody to reduce the frequency and severity of vasomotor symptoms, or hot flashes, in postmenopausal women.

The second phase is a randomized, double-blind, placebo-controlled study in 80 women and follows an interim review of safety, tolerability and pharmacodynamic data from healthy volunteers in the first phase.

AbCellera said the phase 2 enrollment is underway and top-line clinical results for both phases are expected in Q3.

Shares of AbCellera Biologics were up 1.5% in recent trading.

Price: 4.44, Change: +0.06, Percent Change: +1.49

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603544936?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 23:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603544936","market":"hk","top_or_hot":-1,"title":"AbCellera Doses First Patients in Phase 2 Trial of Menopause Drug Candidate","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> (ABCL) said Monday the first patients were dosed in the phase 2 portion of its phase 1/2 trial of ABCL635, an experimental antibody to reduce the frequency and severity of vasomotor symptoms, or hot flashes, in postmenopausal women.</p><p>The second phase is a randomized, double-blind, placebo-controlled study in 80 women and follows an interim review of safety, tolerability and pharmacodynamic data from healthy volunteers in the first phase.</p><p>AbCellera said the phase 2 enrollment is underway and top-line clinical results for both phases are expected in Q3.</p><p>Shares of AbCellera Biologics were up 1.5% in recent trading.</p><p>Price: 4.44, Change: +0.06, Percent Change: +1.49</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbCellera Doses First Patients in Phase 2 Trial of Menopause Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbCellera Doses First Patients in Phase 2 Trial of Menopause Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-12 23:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> (ABCL) said Monday the first patients were dosed in the phase 2 portion of its phase 1/2 trial of ABCL635, an experimental antibody to reduce the frequency and severity of vasomotor symptoms, or hot flashes, in postmenopausal women.</p><p>The second phase is a randomized, double-blind, placebo-controlled study in 80 women and follows an interim review of safety, tolerability and pharmacodynamic data from healthy volunteers in the first phase.</p><p>AbCellera said the phase 2 enrollment is underway and top-line clinical results for both phases are expected in Q3.</p><p>Shares of AbCellera Biologics were up 1.5% in recent trading.</p><p>Price: 4.44, Change: +0.06, Percent Change: +1.49</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603544936","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603544936","pubTimestamp":1768233502,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AbCellera Biologics  said Monday the first patients were dosed in the phase 2 portion of its phase 1/2 trial of ABCL635, an experimental antibody to reduce the frequency and severity of vasomotor symptoms, or hot flashes, in postmenopausal women.The second phase is a randomized, double-blind, placebo-controlled study in 80 women and follows an interim review of safety, tolerability and pharmacodynamic data from healthy volunteers in the first phase.AbCellera said the phase 2 enrollment is underway and top-line clinical results for both phases are expected in Q3.Shares of AbCellera Biologics were up 1.5% in recent trading.Price: 4.44, Change: +0.06, Percent Change: +1.49","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","BK4535":"淡马锡持仓","ABCL":"AbCellera Biologics"},"translate_title":"AbCellera在更年期候选药物2期试验中为第一批患者用药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":1},"content_text":"AbCellera Biologics (ABCL) said Monday the first patients were dosed in the phase 2 portion of its phase 1/2 trial of ABCL635, an experimental antibody to reduce the frequency and severity of vasomotor symptoms, or hot flashes, in postmenopausal women.The second phase is a randomized, double-blind, placebo-controlled study in 80 women and follows an interim review of safety, tolerability and pharmacodynamic data from healthy volunteers in the first phase.AbCellera said the phase 2 enrollment is underway and top-line clinical results for both phases are expected in Q3.Shares of AbCellera Biologics were up 1.5% in recent trading.Price: 4.44, Change: +0.06, Percent Change: +1.49","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603544936","isCrawlerRequest":true}